Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Russia claims to have first COVID-19 vaccine

By Chris Newmarker | August 11, 2020

Russia COVID-19 vaccine

[Image courtesy of Google Maps]

Russian officials announced today that they will make a COVID-19 vaccine available to its citizens on a voluntary basis, with President Vladimir Putin saying the vaccine has gone through all necessary tests.

The vaccine, developed at by the Gamaleya Institute in Moscow, will first become available to medical workers, teachers and at-risk groups. Kirill Dmitriev, chief executive of the Russian Direct Investment Fund that funded the vaccine effort, told reporters that tens of thousands of volunteers will receive vaccinations in the coming months, according to The Associated Press.

Experts even in Russia greeted the news with some skepticism, since the vaccine has not gone through a Phase 3 clinical trial in which its safety and effectiveness is evaluated among a large population with a placebo control group.

NPR reports that the executive director of the Moscow-based Association of Clinical Trials Organizations (ACTO) described the situation as a “Pandora’s Box.”

Danny Altmann, an immunology professor at Imperial College London, told the Science Media Centre: “”The bar is necessarily set very high for criteria that must be satisfied for approval after Phase 3 clinical trials. The collateral damage from release of any vaccine that was less than safe and effective would exacerbate our current problems insurmountably. I hope these criteria have been followed. We are all in this together.”

It’s more important to have a safe and effective COVID-19 vaccine than to be first out of the gate with one, said U.S. Health and Human Services Secretary Alex Azar when asked about the Russian vaccine by reporters while he was visiting Taiwan.

 

 


Filed Under: Infectious Disease
Tagged With: coronavirus, covid-19, Russia
 

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE